OAM
TTNP

Oxford Asset Management’s Titan Pharmaceuticals TTNP Stock Holding History

Oxford Asset Management’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4
Closed -$27K – 1707
2017
Q2 		$27K Buy
+4
New +$37.2K ﹤0.01% 1435

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MERSOM
Municipal Employees' Retirement System of Michigan Lansing, Michigan $8.81B AUM 10.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WPA
Winning Points Advisors Boca Raton, Florida $74.8M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Oxford Asset Management's TTNP Position: Q3 2017 in Review

Oxford Asset Management sold out of Titan Pharmaceuticals (TTNP) in Q3 2017, closing a stake of 4 shares — an estimated $27K sold.

Oxford Asset Management first reported a position in TTNP in Q2 2017 and held it in 1 quarter. The position peaked at $27K in Q2 2017. 24 funds tracked by Wall St. Rank hold TTNP as of Q3 2017.

  • Oxford Asset Management reported no remaining Titan Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Oxford Asset Management sold 4 Titan Pharmaceuticals shares in Q3 2017, an estimated $27K.
  • Oxford Asset Management first reported a position in Titan Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Oxford Asset Management's Titan Pharmaceuticals position peaked at $27K in Q2 2017.
  • 24 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2017.

Based on Oxford Asset Management's 13F filing for Q3 2017, filed 13 Nov 2017.